Second-line targets, such as SLAMF7, CD38, CD138, TACI, and APRIL, possess biological validity, high expression on myeloma cells, and proven therapeutic potential in preclinical and early clinical trials. Here, SLAMF7 is linked to plasma cell myeloma.